PodParley PodParley
PodParley
FDA D.I.S.C.O. Burst Edition: FDA approval of Lynparza (olaparib), with abiraterone and prednisone, for BRCA-mutated metastatic castration-resistant prostate cancer episode artwork

EPISODE · Jul 13, 2023 · 3 MIN

FDA D.I.S.C.O. Burst Edition: FDA approval of Lynparza (olaparib), with abiraterone and prednisone, for BRCA-mutated metastatic castration-resistant prostate cancer

from FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) · host U.S. Food and Drug Administration, Center for Drug Evaluation and Research

Listen to a soundcast of the May 31, 2023, FDA approval of Lynparza (olaparib), with abiraterone and prednisone, for BRCA-mutated metastatic castration-resistant prostate cancer.”

Episode metadata supplied by the publisher feed · Published Jul 13, 2023

Embed this episode

Ready to play

FDA D.I.S.C.O. Burst Edition: FDA approval of Lynparza (olaparib), with abiraterone and prednisone, for BRCA-mutated metastatic castration-resistant prostate cancer

0:00 3:30

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

輕鬆講講故丨粵語丨暴走的陳老C丨廣東話 暴走的陳老C 《輕鬆講講古》

Frequently Asked Questions

How long is this episode of FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)?

This episode is 3 minutes long.

When was this FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) episode published?

This episode was published on July 13, 2023.

Can I download this FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!